Skip to main content
Have a personal or library account? Click to login
Attempts at the development of a recombinant African swine fever virus strain with abrogated EP402R, 9GL, and A238L gene structure using the CRISPR/Cas9 system Cover

Attempts at the development of a recombinant African swine fever virus strain with abrogated EP402R, 9GL, and A238L gene structure using the CRISPR/Cas9 system

Open Access
|Jun 2020

Figures & Tables

Table 1

Target DNA sequences of A238L, EP402R, and 9GL genes of African swine fever strains. Nucleotide positions refer to the ASFV Georgia 2007/1 genome sequence (GenBank accession number FR682468.1). PAM sequences are marked in bold

NameSequencePositionLength
A238L-1CCGAAATAGCCCAACACCCCTTC50.832–50.85120
A238L-2TCGCATCTATTGACAATCCACGG51.027–51.04620
EP402R-1CCTCATAATGATGTATTTGATAC73.627–73.64620
EP402R-2CCTGCTACTCCCCCAAATATCAC73.705–73.72420
9GL-1CCAGTACTGAAAGTCCTCCGAG95.099–95.11719
9GL-2CCAGTATTTAGGTCCCCAATGCA95.285–95.30420
Fig. 1

Schematic representation of the selection of the suitable transfection kit and target cells

Table 2

Transfection protocol. The main conditions for two applied kits are presented

ParameterXfectGeneJect
Plasmid DNA5 μg0.4 μg
Total growth medium volume1,000 μL1,000 μL
Transfection reagent1.5 μL2 μL
Incubation time for nanocomplexes creation10 min/RT30 min/RT
Incubation time with target cells4 h/37°C24–72 h/37°C
Additional stepsDisposal Replacement of medium with fresh growth medium-
Control of transfection effect48 hWithin 24–72 h incubation time

[i] RT – room temperature

Table 3

Primers used for amplification of the region of interest covering target genes. Nucleotide positions refer to the ASFV Georgia 2007/1 genome sequence (GenBank accession number: FR682468.1)

NameSequencePositionTm (Primer melting temperature)
A238L-FTTGGACACAGGAAACGATCT50.370–50.38949.7°C
A238L-RATATGGGAAAAGGGCCTGGC51.302–51.28353.8°C
EP402R-FACTATATTATAAAACATATG73.341–73.36037.4°C°
EP402R-RTGCATGTGATGGAAATCGGT74.594–74.57549.7°C
9GL-FGCCTCACTATCGATCGGCAA94.046–94.06553.8°C
9GL-RACTGGCTGGAATTACGCCAA95.450–95.43151.8°C
A224L-FAAAAGCTATTTGTTTATCCCCA46.266–46.28747.4°C
A224L-RCCTTCAATTGAGGATGATCATT47.057–47.03649.2°C
Fig. 2

Vero cells transfected with constructed CRISPR/Cas9 plasmid. In order to confirm successful transfection, a puromycin selection was applied, which led to an increased rate of cell death during the first three days post transfection, and later the cell culture started to grow in antibiotic supplemented medium (magnification 200 ×)

Table 4

Results obtained in real-time PCR

Target sitePPAM Puromycin 24 hPPAM Puromycin 48 hPBM Puromycin 24 hPBM Puromycin 48 h
IIIIIIIIIIII
9GL-133.89h33.85h34.14h35.9731.95 h-31.48h38.62
9GL-234.49h31.05h34.38h31.99h31.65 h33.55h32.37h34.08
A238L-132.26h31.3h32.75h31.26h32.34 h28.5h32.88h-
A238L-232.92h31.93h32.92h29.88h31.93 h30.52h33.61 h35.54
EP402R-131.92h38.7133h29.76h32.74 h34.2132.9h33.79 h
EP402R-231.79h28.82h32.8h36.2532.89 h38.6932.59h34.81

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

h haemadsorption; I (II) – first (second) passage after 24 (48) h of incubation with puromycin

Fig. 3

Agarose gel (2%) showing the results of the conventional PCR to amplify whole sequences of targeted genes. Gene names at the top represent the amplified region. Numbers below gene names correspond to Table 5 numbers in brackets, 1000/500 – band size markers

Table 5

Results of conventional PCR

MaterialPCR target
9GLA238LEP402RA224L
KO-9GL1(2)−n/an/a(5)−
KO-9GL2(3)−n/an/a(6)+
KO-A238L1n/a(8)+n/a(11)+
KO-A238L2n/a(9)+n/a(12)+
KO-EP402R1n/an/a(14)−(17)+
KO-EP402R2n/an/a(15)−(18)−
WT(4)+(10)+(16)+(7, 13, 19)+

[i] Numbers in brackets represent sample numbers in Fig. 3. KO – knock-out targets;

WT – wild type; n/a – not applicable

Fig. 4

In vitro replication kinetics of the six generated deletion mutant (A – 9GL1Δ; B – 9GL2Δ; C – A238L1Δ; D – A238L2Δ; E – EP402R1Δ; F – EP402R2Δ) and parent ASFV/Pol18/28298/O111 isolates. PPAM cell cultures were infected (MOI 0.1) with both strains, and subsequently virus titres were estimated daily over 96 h post infection. Data represent means and standard deviations from three independent experiments. The sensitivity of virus detection was 1.8 HAD50/mL

DOI: https://doi.org/10.2478/jvetres-2020-0039 | Journal eISSN: 2450-8608 (formerly 2300-3235)
Language: English
Page range: 197 - 205
Submitted on: Oct 4, 2019
Accepted on: May 25, 2020
Published on: Jun 3, 2020
Published by: National Veterinary Research Institute in Pulawy
In partnership with: Paradigm Publishing Services

© 2020 Grzegorz Woźniakowski, Natalia Mazur-Panasiuk, Marek Walczak, Małgorzata Juszkiewicz, Maciej Frant, Krzysztof Niemczuk, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.